Alps Advisors Inc. purchased a new stake in EXACT Sciences Co. (NASDAQ:EXAS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 3,998 shares of the medical research company’s stock, valued at approximately $210,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Chicago Equity Partners LLC purchased a new stake in EXACT Sciences in the 3rd quarter valued at about $2,312,000. Bank of Nova Scotia purchased a new stake in EXACT Sciences in the 2nd quarter valued at about $1,482,000. Stifel Financial Corp grew its holdings in EXACT Sciences by 16.5% in the 2nd quarter. Stifel Financial Corp now owns 25,023 shares of the medical research company’s stock valued at $888,000 after buying an additional 3,548 shares during the period. Sit Investment Associates Inc. grew its holdings in EXACT Sciences by 168.2% in the 3rd quarter. Sit Investment Associates Inc. now owns 29,900 shares of the medical research company’s stock valued at $1,409,000 after buying an additional 18,750 shares during the period. Finally, Columbus Circle Investors grew its holdings in EXACT Sciences by 5.5% in the 3rd quarter. Columbus Circle Investors now owns 133,398 shares of the medical research company’s stock valued at $6,286,000 after buying an additional 6,965 shares during the period. Institutional investors own 83.12% of the company’s stock.
Several analysts have commented on the company. Leerink Swann set a $67.00 price target on EXACT Sciences and gave the company a “buy” rating in a report on Friday, February 9th. BidaskClub upgraded EXACT Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 7th. Goldman Sachs Group assumed coverage on EXACT Sciences in a report on Monday, January 29th. They issued a “neutral” rating and a $51.00 price target for the company. Zacks Investment Research cut EXACT Sciences from a “buy” rating to a “hold” rating in a report on Friday, January 19th. Finally, Benchmark set a $65.00 price target on EXACT Sciences and gave the company a “buy” rating in a report on Wednesday, January 17th. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. EXACT Sciences currently has a consensus rating of “Buy” and a consensus target price of $52.84.
Shares of EXACT Sciences Co. (NASDAQ EXAS) opened at $49.14 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. EXACT Sciences Co. has a fifty-two week low of $19.54 and a fifty-two week high of $63.60.
In other news, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $59.50, for a total transaction of $7,976,391.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin T. Conroy sold 121,849 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.45, for a total value of $6,512,829.05. Following the sale, the insider now owns 951,901 shares of the company’s stock, valued at approximately $50,879,108.45. The disclosure for this sale can be found here. Insiders have sold a total of 764,182 shares of company stock valued at $40,574,047 in the last quarter. Company insiders own 4.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Alps Advisors Inc. Purchases Shares of 3,998 EXACT Sciences Co. (EXAS)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/16/alps-advisors-inc-purchases-shares-of-3998-exact-sciences-co-exas.html.
EXACT Sciences Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.